Back

Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

6 More presentations in this session

Presentation thumbnail
Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF
Doctor C. Emter (Boulder, US)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic implications of frailty and other geriatric conditions in patients with transthyretin amyloid cardiomyopathy. The AMYLO-FRAIL study.
Doctor M. Antunez-Ballesteros (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Silencing TTR, distinct signals: safety profiles of small interfering RNA therapies in amyloidosis
Mrs J. Gu (Erie, US)
Abstract Slides Video
Presentation thumbnail
Transthyretin gene silencing therapy in Val50Met familial amyloid polyneuropathy with associated cardiomyopathy
Doctor P. Monteiro (Porto, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Silencing TTR, distinct signals: safety profiles of small interfering RNA therapies in amyloidosis
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies
thumbnail
Congress Presentation
Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources